Project Grant R44DA042652

The National Science Foundation (NSF) Division of Information and Intelligent Systems awarded a $162,827 Project Grant to the University of Wisconsin - Madison, through the University of Wisconsin System, to develop an "Intelligent Pervasive Augmented Reality Therapy (IPAL)" system for managing opioid use disorder (OUD) and addiction. The 1-year project will integrate complementary psychotherapies like cognitive behavioral therapy and heart rate variability biofeedback with immersive...

The National Institute on Drug Abuse (NIDA) awarded a $2,729,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Rhode Island. The purpose of this 2-year award, with a start date of September 15, 2024, is to rigorously develop and evaluate a mobile health intervention for adults with co-occurring opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) during community re-entry after residential OUD treatment. The proposed mobile app...

This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...

The National Institute on Drug Abuse (NIDA) awarded a $188,307 Project Grant to the University of Pittsburgh under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 1, 2025, through August 31, 2029. This award supports the development and testing of a guided, web-based behavioral treatment intervention that combines Acceptance and Commitment Therapy (ACT) for chronic pain with Mindfulness-Based Relapse Prevention (MBRP) for substance use disorders. The research...

PEACE Platform Development and Evaluation Biomotivate LLC received $613,744 under a Project Grant from the National Institute on Drug Abuse (NIDA) Drug Use and Addiction Research Programs (CFDA 93.279), awarded August 1, 2025, with completion targeted for July 31, 2026. The award funds development and evaluation of the PEACE Platform (Personalized Evocative Audiovisual Content for Everyone), a precision medicine tool designed to complement existing opioid use disorder (OUD) treatment...

Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $933,000 to the University of Wisconsin–Madison under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2025, for development and evaluation of FamilyChess, a family-focused digital intervention designed to improve medication for opioid use disorder (MOUD) initiation and retention. The project addresses the critical public health gap where only 22% of individuals with opioid use...

This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...

Federal Cooperative Agreement Summary Virginia Commonwealth University, in collaboration with Vivozon Inc., received a $2.31 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop preliminary safety and efficacy data for VVZ-2471, a novel 5-HT2A/mGluR5 (metabotropic glutamate receptor 5) antagonist as an adjunctive treatment for opioid use disorder (OUD). The award, effective September 15, 2025,...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a software-based medical device (SAMD) for detecting opioid use through voice analysis. The $800,000 award to Tenvos Inc., a minority-owned and woman-owned technology company, aims to advance the company's AI-driven solution that can enable patients to remotely test for opioid use and securely share results with...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...